Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer

Annals of Oncology

Volumn 9, Issue 5, 1998, Pages 505-509

  Buntzel J ^a,b   Kuttner K ^a   Frohlich D ^b   Glatzel, M ^b  

^a Ear   (Germany)

^b Klinikum Suhl   (Germany)

Author keywords

Amifostine; Concurrent chemo and radiation therapy; Head and neck cancer; Reduced toxicity; Selective cytoprotection

Indexed keywords

AMIFOSTINE; CARBOPLATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CELL PROTECTION; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEAD AND NECK CANCER; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; XEROSTOMIA;

ADULT; AGED; AMIFOSTINE; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; CYTOPROTECTION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; RADIATION-PROTECTIVE AGENTS;

EID: 0031840023     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008282412670     Document Type: Article

References (24)

1. Kashima HK, Kirkham WR, Andrews JR. Postirradiation sialadenitis: A study of the clinical features, histopathologic changes and serum enzyme variations following irradiation of human salivary glands. Am J Roentgenol Radiat Ther Nucl Med 1965; 94 (2): 271-91.
2. Delaney GP, Fisher RJ, Smee RI et al. Split-course acclerated therapy in head and neck cancer: An analysis of toxicity. Int J Radiat Oncol Biol Phys 1995; 32: 763-8.
3. Bourhis J, Fortin A, Dupuis O et al. Very accelerated radiation therapy: Preliminary results in locally unresectable head and neck carcinomas. Int J Radial Oncol Biol Phys 1995; 32: 747-52.
4. Dreizen S, Brown LR, Daly TE, Drane JB. Prevention of xerostomia-related dental caries in irradiated cancer patients. J Dent Res 1977; 56: 99-104.
5. Regezi JA, Courtney RM, Kerr DA. Dental management of patients irradiated for oral cancer. Cancer 1976; 38 (2): 994-1000.
6. Dimery IW, Hong WK, Overview of combine modality therapies for head and neck cancer. J Nail Cancer Inst 1993; 85: 95-111.
7. Vokes EE, Weighselbaum RR, Lippman SM, Hong WK. Medical progress: Head and neck cancer. N Engl J Med 1993; 328: 184-94.
8. Merlano M, Vitale V, Rosso R et al. Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N Engl J Med 1992; 327: 1115-21.
9. Yuhas JM. Biological factors affecting the radioprotective efficiency of S-2-[3-Aminopropylamino] ethylphosphorothioic acid (WR-2721): LD50(3) doses. Radiat Res 1970; 44: 621 8.
10. Dendale R, Bourhis J, Diawara O et al. Effect of systemic and topical administration of amifostine on radiation-induced mucositis in mice. Proc Am Soc Clin Oncol 1997; 16: 64a (Abstr).
11. Sodicoff M, Conger AD, Pratt NE. Trepper P. Radioprotection by WR-2721 against long-term chronic damage to the rat parotid gland. Radiat Res 1978; 76: 172-9.
12. Sodicoff M, Conger AD, Trepper P, Pratt NE. Short-term radioprotective effects of WR-2721 on the rat parotid glands. Radiat Res 1978; 75: 317 26.
13. Liu T, Liu Y, He S et al. Use of radiation with or without WR-2721 in advanced rectal cancer. Cancer 1992; 69: 2820-5.
14. McDonald S, Meyerowitz C, Smudzin T, Rubin P. Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland disfunction, Int J Radiat Oncol Biol Phys 1994; 29 (4): 747-54.
15. Takahashi I, Nagai T, Miyaishi K et al. Clinical study of the radioprotective effects of amifostine (YM-08310, WR-2721) on chronic radiation injury. Int J Radiat Oncol Biol Phys 1986; 12: 935-8.
16. Kemp G, Rose P, Lurain J et al. Amifostine pretreatment for protection against cyclophosphamide-and cisplatin-induced toxicities: Results of a randomised control trial in patients with advanced ovarian cancer. J Clin Oncol 1996; 14: 2101-12.
17. Betticher DC, Anderson H, Ranson M et al. Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: A randomised phase II study. Br J Cancer 1995; 72 (6): 1551 5.
18. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting Results of Cancer Treatment. Cancer 1981; 47: 207-14.
19. American Cancer Society. Cancer facts and figures 1996. Published Data Report 1996.
20. Al-Sarraf M. Head and Neck Cancer: Chemotherapy Concepts. Semin Oncol 1988; 15: 70-85.
21. Wibault P, Bensmaïne ME, de Forni M et al. Intensive concomitant chemoradiotherapy in locally advanced unresectable squamous cell carcinoma of the head and neck: A phase II study of radiotherapy with cisplatin and seven-week continuous infusional fluorouracil. J Clin Oncol 1996; 14 (4): 1192-200.
22. El-Sayed S, Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region: A meta-analysis of prospective and randomized trials. J Clin Oncol 1996; 14: 838-47.
23. Merlano J, Benasso M, Corvö R et al. Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst 1996; 88 (9): 583 9.
24. Tanaka Y. Protective effects of WR-2721 against to the local irradiation and its clinical application. J Radiat Res 1980; 21: 76-7.